Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescr

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering.

Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
  • Assess the commercial outlook for key new launch products Effient and Bydureon
  • Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa, Cymbalta and other key franchises over the period 2011-14

Key Topics Covered:

Chapter 1 About this profile

Chapter 2 Executive summary Chapter 3 Quarterly news update

Chapter 4 Company introduction

Chapter 5 Company sales

Chapter 6 Company financials

Chapter 7 Key products and competitors

Chapter 8 Appendix

Companies Mentioned:

  • Abbott Laboratories
  • ACS Motion Control Ltd
  • Alkermes Inc
  • Amylin Pharmaceuticals Inc
  • AstraZeneca PLC
  • Automatic Data Processing, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cephalon
  • Chugai Pharmaceutical Co. Ltd
  • Citizen Electronics Company Limited
  • Daiichi Sankyo, Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Impax Laboratories, Inc.
  • IMS Health
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NICE Systems Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Pivotal Corporation

For more information visit http://www.researchandmarkets.com/research/37adf0/eli_lilly_co_p

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.